Inside a $58 Million Bet on Kodiak Amid $184 Million Offering and Phase 3 Readouts Ahead
2026-02-19 17:34:01 ET
On February 17, 2026, Connecticut-based Braidwell disclosed a new position in Kodiak Sciences (NASDAQ:KOD) , acquiring 2,072,788 shares in a trade estimated at $57.96 million.
Braidwell LP reported a new holding in Kodiak Sciences, acquiring 2,072,788 shares during the fourth quarter of 2025, according to an SEC filing dated February 17, 2026. The quarter-end position value stood at $57.96 million, capturing both share purchases and price movements.
Kodiak Sciences is a biotechnology company focused on the research and development of innovative therapies for retinal diseases. With a pipeline led by KSI-301 and supported by additional preclinical candidates, the company leverages advanced antibody biopolymer technology to address significant unmet medical needs in ophthalmology.
NASDAQ: KOD
KOD Trading
2.41% G/L:
$24.69 Last:
237,674 Volume:
$24.24 Open:
